ADGI Potential Neutralizing Activity Against Covid-19 VariantsAdagio Therapeutics announced its lead monoclonal antibody has neutralization activity against the Omicron variant of SARS-CoV-2.
Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for prevention and treatment of COVID-19.
Adagio is engaging with the FDA regarding protocol updates to its global Phase 2/3 clinical trials.
My price target is the $14.5 resistance.
Vaccine
ARDS Covid-19 Antibody Cocktail | Massive Bullish DivergenceThe chart speaks for itself: ARDS is in a massive bullish divergence at all time low levels from which can explode anytime soon!
Recently, analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS , told investors that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."
Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated."
ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS , and the Common Cold Human Coronaviruses.
It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment.
Market Cap 27.124Mil
52 Week Range 1.89 - 8.47
I think this might be our 10X stock for 2022.
NOVAVAX Fractal and Symmetric trianglefirst of all thanks for stopping by.. This text below will be posted on every timeframe
Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar .
On the big picture I'm looking at the 2 monthly chart
To remove some noise and get a good idea of the price, I find a DRABW Right Angled Descending Broadening Wedge here, often a Bullish pattern . At the top we see that another support line has been found where the bulls can prepare themself to make an attempt to attack the upper resistance / ATH again. see also in this picture the divergence that has managed to make a considerable run up. Here it is also nice to see how the share price reacts to favorable news for a company like this.
To stay in the even number, we zoom in slightly to the 2W chart.
here we see very nicely how a Bump and Run is rejected on the 0.382 of the fibonacci, the price just looks up the trend channel and from there the bulls make another attack on the resistance line (Lead-in) and with succes. So mirroring the pattern could give an idea for where it could go .. and so we have now ended up in a symmetrical triangle i even think that in an EW count, this could be an Ending diagonal or a correction wave. and after a corrective wave comes another impulse wave (up or down).
Ending with the day chart. zoomed in on the symmetrical triangle.
good to see how the pressure is on the top in the pattern. and the picture is how the situation is. you could even spot a fractal white squares and if it would continue, which means that it could happen again. So keep an eye out and look for supporting within the pattern.
Keep calm, do your own research! trade safe and manage your risk.
*(Disclaimer: This is not financial advice)
NOVAVAX BARR into Symmetric trainglefirst of all thanks for stopping by.. This text below will be posted on every timeframe
Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar .
On the big picture I'm looking at the 2 monthly chart
To remove some noise and get a good idea of the price, I find a DRABW Right Angled Descending Broadening Wedge here, often a Bullish pattern . At the top we see that another support line has been found where the bulls can prepare themself to make an attempt to attack the upper resistance / ATH again. see also in this picture the divergence that has managed to make a considerable run up. Here it is also nice to see how the share price reacts to favorable news for a company like this.
To stay in the even number, we zoom in slightly to the 2W chart.
here we see very nicely how a Bump and Run is rejected on the 0.382 of the fibonacci, the price just looks up the trend channel and from there the bulls make another attack on the resistance line (Lead-in) and with succes. So mirroring the pattern could give an idea for where it could go .. and so we have now ended up in a symmetrical triangle i even think that in an EW count, this could be an Ending diagonal or a correction wave. and after a corrective wave comes another impulse wave (up or down).
Ending with the day chart. zoomed in on the symmetrical triangle.
good to see how the pressure is on the top in the pattern. and the picture is how the situation is. you could even spot a fractal white squares and if it would continue, which means that it could happen again. So keep an eye out and look for supporting within the pattern.
Keep calm, do your own research! trade safe and manage your risk.
*(Disclaimer: This is not financial advice)
NOVAVAX DRABW first of all thanks for stopping by.. This text below will be posted on every timeframe
Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar .
On the big picture I'm looking at the 2 monthly chart
To remove some noise and get a good idea of the price, I find a DRABW Right Angled Descending Broadening Wedge here, often a Bullish pattern . At the top we see that another support line has been found where the bulls can prepare themself to make an attempt to attack the upper resistance / ATH again. see also in this picture the divergence that has managed to make a considerable run up. Here it is also nice to see how the share price reacts to favorable news for a company like this.
To stay in the even number, we zoom in slightly to the 2W chart.
here we see very nicely how a Bump and Run is rejected on the 0.382 of the fibonacci, the price just looks up the trend channel and from there the bulls make another attack on the resistance line (Lead-in) and with succes. So mirroring the pattern could give an idea for where it could go .. and so we have now ended up in a symmetrical triangle i even think that in an EW count, this could be an Ending diagonal or a correction wave. and after a corrective wave comes another impulse wave (up or down).
Ending with the day chart. zoomed in on the symmetrical triangle.
good to see how the pressure is on the top in the pattern. and the picture is how the situation is. you could even spot a fractal white squares and if it would continue, which means that it could happen again. So keep an eye out and look for supporting within the pattern.
Keep calm, do your own research! trade safe and manage your risk.
*(Disclaimer: This is not financial advice)
PFE to the DownsideThere is so much baked into the markets with vaccines. I expect PFE to have some downside to 55.66 to 55.47 as a T1 downside Target.
$ARCT is a BUY nowArcturus Therapeutics Holdings Inc. $ARCT is set to be EBITDA positive in 2022 with a massive change in its revenue from 24.05M in 2021 to 326.44M in 2022. This is 12.57x increase in revenue. These numbers are estimates, but even with a large error margin we should see a drastic change in the price. Moreover, the decline from ATH was 80% and the price has been in a sideways movement after it bottomed. With today's strong breakout of the descending channel, I am expecting the price to start its rise up to the upper band of the range-bound around $63. The long-term targets should be a lot higher.
The breakout setup entry provides us with an awesome +3 Reward/Risk. A tighter stop loss order can even make it a lot better. A late entry at current prices provides 1.8-2.0 which is still a good ratio.
BioTech stocks are risky and volatile. This is not financial advice. DYODD
OCGN COVAXIN Robust Immune Memory to COVID-19 and VariantsNew Data suggest COVAXIN (BBV152) may provide protection against current and future variants!
data from a Phase 3 trial that included nearly 25,800 participants: 77.8% overall efficacy, 93.4% efficacy against severe illness and 65.2% efficacy against the Delta variant.
52 Week Range 0.28 - 18.77
My price target is the 10.30usd resistance.
Pox Vaccine/Treatment Long, Dark WinterWith the small rise of pox news going on in the U.S., be it the second case of monkeypox this year , to smallpox vials found at a vaccine research facility in Pennsylvania, it brings to question as to whether or not health companies that have the capability to manufacture vaccines, treatments, and test kits against smallpox will be the new growth sector of vaccine stocks in the future.
Although smallpox is considered eradicated since 1980, considering other variants of smallpox like monkeypox are still present in this world and the lack of immunity among the young (people under the age of 35) from the closure of smallpox vaccine production (we're talking about a ~ 15% fatality rate that goes up to ~40% the younger a person is ), it is still a clear and present danger to society. Doesn't help that the FDA has been more active in approving multiple vaccines and treatments over the last 3 years. . Though the good news is that the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) will target to stockpile enough vaccines for every American according to a 2016 report .
PREVENTION
As of my knowledge, the following stocks hold a trademark of a vaccine against smallpox:
- $EBS, ACAM2000 ®
- $BVNRY, holds a trademark of a vaccine against monkeypox, named JYNNEOS® under the FDA . For tradenames of this vaccine under other regions, see the investor news page published this july .Note the JYNNEOS vaccine is the only currently FDA-approved vaccine for the prevention of monkeypox disease and smallpox. These vaccines are not readily available to public, but several treatments are ... more on that below.
- $SNY, the Aventis Pasteur Smallpox Vaccine (APSV), that is available in the event that ACAM2000® is depleted within the U.S. Strategic National Stockpile (SNS) which apparently holds 90M doses . Note Aventis was merged with Sanofi in 2004, just to clear up any confusion on any old web pages from before 2004.
More details about these vaccines can be found here:
www.cdc.gov
www.cdc.gov
www.fda.gov
You could argue $NVAX to be a good pick but I would consider it a long-term play.
TREATMENTS
The following stocks hold a trademarked treatment against smallpox:
- $SIGA , TPOXX® , also known as tecovirimat and ST-246®
- $CMRX , Tembexa (brincidofovir)
There are many more companies working on treatments/detections against smallpox, so feel free to research and find them before they go public. This idea is merely an inspiration for you to look for and capitalize on this opportunity if it presents itself in the future.
Take BioFire as an example, a private company contracted by the DoD to supply them test kits on various biological warfare agents including smallpox . ( Pg 105 of 2016 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan). But although there private, they've merged w/ bioMerieux , a publicly-traded company, in January 2014. In the event that the supply of vaccines does meet demand, this could be an alternative strategy seeing as test detection kits may not be in demand at the moment. Especially considering that the awarded NGDS contract was valued at $240M for a period of 8 years, or $30M per year(which corresponds very closely with how much $ was allocated toward JOINT BIOLOGICAL AGENT DECONTAMINATION SYSTEM (JBADS) according to the UNCLASSIFIED Department of Defense Fiscal Year (FY) 2022 Budget Estimates document released in May this year on Page 2 of 91, P-1 line #80 titled CB Protection & Hazard Mitigation, or just page 142 of 754 of the pdf doc). With each kit costing $8K-$9k each for 30 tests , at max the DoD should hold ~30K kits assuming these kits have not been used and have an extended shelf life beyond the lifetime of the awarded gov. contract, and that this budget does not include any other products from BioFire related to the NGDS. 30K units with 30 tests each means 900,000 total possible tests... if they're single-use, it may not be even enough for essential personnel contracted by the gov. Even if you consider smallpox's eradication... it is not reasonable for the gov to spend a bit more on these kits seeing they cover detection on outbreaks outside of smallpox like anthrax, ebola, etc.
Thankfully Bill Gates did warn us of bioterror attacks concerning smallpox earlier this year. The same goes for U.S. Government agencies and institutions' wargaming of such an event back in 2001, naming the exercise, Dark Winter .
A couple of interesting conclusions from this exercise:
-No surge capacity in U.S. healthcare and public health systems. Given how COVID-19 went, not too surprising but as expected
-Information management w/ media be crucial for crisis control. Lol, w/ the amount of distrust in the media and gov. this will be sh*tshow. Don't be surprised by draconian levels of control over the flow of info if this outbreak happens.
-Renewed vaccine production is estimated to require at least 24-36 months. Big yikes.
If a smallpox breakout does happen and vaccine hesitancy continues w/ smallpox vaccines, let alone the supply of these products not being able to catch up to their demand, expect a high amount of casualties and stocks related to the treatment rather than the prevention of smallpox to rise. Nonetheless, the living will be capable of seeing a new and brighter world of the 4th industrial revolution by 2030.
Feel free to comment below on any constructive criticism against this idea. I'd like to strengthen it and improve on the quality of future ideas. If my grammar is bad, it is no excuse, but I was raised with poor primary education, it will get better with time. If you agree with this idea, feel free to leave a like and share, thank you.
PFE Pfizer to All Time HighIf you haven`t bought at my first call, when PFE was $40:
Than you should know that Pfizer’s vaccine with BioNTech SE is on track to be the best-selling drug product on a yearly basis and received backing from a European regulatory panel on Thursday to expand its use into children as young as five.
Still low PE Ratio (TTM) 15.42
Decent Forward Dividend & Yield 1.56 (2.89%)
The stock jumped also on the promise of its antiviral pill!
For me is a Buy even at this level!
$BNTX^ $BNTX will announce if its possible to revise their current vaccine to accommodate the new strain in 2 weeks and could redesign its vaccine within 6 weeks, with an aim to distribute it within 100 days.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
11/29 - 12/03 | $MRNA | Watchlist #3$MRNA $308 or $300 bounce
(If we get below then reclaim these levels, take a position for calls)
Price targets:
308->310
300->305
Technical analysis: Bounce off pivot point around 308 area or bounce off psychological level at 300
Rationale: With increasing news of a new virus variant, vaccine stocks are rallying so there is built up potential for more momentum
$MRNAModerna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, Metagenomi, Inc., and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd.; Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group; Aldevron, LLC; Institute for Life Changing Medicines; and AbCellera Biologics Inc. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
TMBR Timber Pharmaceuticals Upside PotentialTMBR Timber Pharmaceuticals had a recent public offering price of $0.64 per share of common stock and accompanying common warrant. The warrants have an exercise price of $0.70 per share.
The price is now 0.47usd
There is a strong upside potential short term!
Price Target 1: $0.85
Price Target 2: $1.37
Stop loss: $0.41
Looking forward to read your opinion about it.
our beloved $ATOS *This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
$ATOS remains my teams best trade yet, but sadly for you guys this was before we got serious about documenting our trades here at tradingview. Long story short our guys charted and caught an enormous jump from $1.50 to $9+ per share earlier this year.
My team entered $ATOS again today at $2.75 per share and have set our first take profit at $4.
ENTRY: $2.75
TAKE PROFIT 1: $4
TAKE PROFIT 2: $6.50
If you want to see more, please like and follow us @SimplyShowMeTheMoney
NVAX BUY (NOVAVAX INC)Hi there.
Price is forming a continuation pattern to the upside.
Watch strong price action at the current levels for buy.
HGEN in EU Commission 10 Most Promising Treatments for COVID-19!European Commission’s independent experts selected Humanigen’s Lenzilumab as One of the 10 Most Promising Treatments for COVID-19!
CEO of Humanigen said today: "We look forward to continuing our discussions with colleagues at the European Medicines Agency to advance our efforts to submit a marketing authorization application for lenzilumab in COVID-19".
In the same list you can see Pfizer, Roche, Astra Zeneca and Eli Lilly! Humanigen is the smallest company.
Institutions loaded big on this dip of Humanigen, Inc. (HGEN), 132Mil in the last quarter!
On 8/23/2021 Morgan Stanley reported an increased ownership in HGEN by +1,884.6%!
Biggest shareholder is Blackrock with 3,037,693 shares worth $52.80Mil, which increased its position by +283.5% for a total ownership of 5.141% of Humanigen.
So Blackrock paid an average of 17.3usd per share!
The price of the stock is now 6.60usd!
H.C. Wainwright’s Joseph Pantginis rates HGEN a Buy along with a $28 price target and said the market overreacted on that selloff.
My price target is the 16.3usd resistance!
$MRK: Vaccine KrptoniteInvestors should continue to watch Merck and how it plays out here at the 80 level as their COVID drug treatment is pending approval. I believe the market is absolutely sleeping on the significance of this drug and the kind of impact it will have. A treatment is an absolute game changer provided the politics of COVID do not disrupt innovation, transparency and competition in the market. If Merck's drug is effective at treating COVID this will be disastrous to companies like MRNA, JNJ, DVAX, PFE and NVAX. Currently, we're still sitting at less than a 60% fully vaccinated population, the tightest labor supply in history and a work force petitioning vaccine mandates as was witnessed with Boeing workers in Seattle. This will force lawmakers hands to suspend vaccine mandates indefinitely crashing demand for vaccines in the future. The US population has made their stance and vaccine persuasion will only have a diminishing effect from here on out, so the only option is the option that works for everyone in order to minimize division in the country.
Stocks - MRNA Short (S3) Aug 13 TargetIdea for MRNA:
- Good level for reversal. Aug 13 is the capitulation date.
- Stop is at 41 degrees.
- Gamma squeeze bubble ends with big deflation.
TP1: Gap fill 260~
PT 0.5 retrace of move:
GLHF
- DPT
MRNAModerna broke weekly support making this very vulnerable towards 237-250$/share.
Will fall pretty hard in coming days - weeks iMO.
Overvalued af in the high 400's nearly cut in half but not quite yet .. currently in puts.
MODERNA POSSIBLE DISTRIBUTION!Hello my beauties.
I think MRNA has entered a distribution range, as the ST (second test) seemed to be pretty weak, and the price is now showing weakness below the trading range. We are going to wait for further developments in price action and eventually take a trade on the final LPSY. For those of you who like trading ranges, this might be a juicy opportunity. Watch for the creation of an UT (upthrust) and an UTAD (upthrust after distribution) before you take your trade.
If you find this idea to be helpful like, follow, and drop a comment below if you'd want me to analyse a different pair.
Consider supporting me if you think I am providing you with value.
Peace.
Luca, TrickleDownFX
Pharmaniaga - TP at 6 range possible?MYX:PHARMA
With recent business deal signings will the punters back to this counter?
From 2-3 days observation, personally this counter may still overlooked with addition of MCO 2.0 being introduced - the volume is just not there (yet?)
Like it or not 14mils doses has been bought even some may decries the subpar 50%++ effective rate of Sinovac covid19 vaccine that being shared by certain country.
The stock best performance was recorded last Aug, where the price hit 6.69 which is a handsome multiplier of the price prior to covid era averaging ~2 in last Jan-Feb
*This is not a call sign - the writer can't confirm or deny any dealings related to this stock
$PFE RSI bullish divergenceStill swinging Pfizer calls. Bullish divergence on RSI indicator 1HR
Still holding longer term uptrend.
Mid October - NOV 45Cs as an idea or credit spread 45/40P
Break below black line invalidates trade idea
